The GMEB1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal pool derived from the Raji B-lymphocyte cell line, engineered to abolish expression of the Glucocorticoid Modulatory Element Binding Protein 1 (GMEB1). This polyclonal knockout population provides a robust loss-of-function model system for dissecting GMEB1-dependent transcriptional regulation and signaling in a B-cell context. The use of a polyclonal CRISPR-edited pool minimizes clonal artifacts and captures heterogeneous cellular responses, offering a physiologically relevant system for functional studies.
Raji is an EBV-positive Burkitt’s lymphoma cell line exhibiting B-cell surface markers CD19 and CD20, and serves as a standard model for B-cell malignancies and immune signaling studies. Its transformed phenotype and defined signaling pathways make it ideal for investigating oncogenic mechanisms and therapeutic responses in lymphoid cancers.
GMEB1 functions as a transcriptional cofactor that modulates glucocorticoid receptor (GR/NR3C1) activity by binding to glucocorticoid modulatory elements (GMEs) in target gene promoters. It is activated by upstream signals including glucocorticoids, inflammatory cytokines such as TNF-??, and stress-activated MAP kinases JNK and p38. GMEB1 interacts with importin-?? (KPNA2), HSP90, MDM2, and the ubiquitin ligase UBE3A/E6AP to regulate GR transactivation and stability. Downstream, GMEB1 controls the expression of BIM (BCL2L11), FKBP5, and GILZ (TSC22D3), linking it to apoptosis and stress responses. GMEB1 also crosstalks with NF-??B (RELA) signaling pathways, integrating survival and apoptotic cues.
In the Raji B-cell lymphoma context, disruption of GMEB1 is expected to profoundly alter GR-dependent gene expression programs, impacting apoptosis, proliferation, and NF-??B-mediated survival signaling. Given the reliance of B-cell malignancies on glucocorticoid signaling for both growth control and therapeutic responses (e.g., dexamethasone-induced apoptosis), loss of GMEB1 serves as a powerful tool to dissect mechanisms of glucocorticoid resistance and to identify GMEB1-dependent vulnerabilities. This model enables the study of how GMEB1 modulates the balance between BIM-induced apoptosis and NF-??B-driven survival in EBV-positive lymphoma cells.
Applications include Western blotting and RT-qPCR for expression analysis, glucocorticoid-responsive luciferase reporter assays, Annexin V apoptosis assays, and co-immunoprecipitation of GR?CGMEB1 complexes. Drug sensitivity testing with dexamethasone can reveal shifts in glucocorticoid responsiveness, while flow cytometry for CD19/CD20 and NF-??B markers enables phenotypic and signaling characterization. For additional details, please contact Ascent Research.
